{"pmid":32393351,"title":"Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19.","text":["Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19.","BACKGROUND: The triglyceride and glucose index (TyG) has been proposed as a marker of insulin resistance. This study aims to evaluate the association of the TyG index with the severity and mortality of coronavirus disease 2019 (COVID-19). METHODS: The study included a cohort of 151 patients with COVID-19 admitted in a tertiary teaching hospital in Wuhan. Regression models were used to investigate the association between TyG with severity and mortality of COVID-19. RESULTS: In this cohort, 39 (25.8%) patients had diabetes, 62 (41.1%) patients were severe cases, while 33 (22.0%) patients died in hospital. The TyG index levels were significantly higher in the severe cases and death group (mild vs. severe 8.7 +/- 0.6 vs. 9.2 +/- 0.6, P < 0.001; survivor vs. deceased 8.8 +/- 0.6 vs. 9.3 +/- 0.7, P < 0.001), respectively. The TyG index was significantly associated with an increased risk of severe case and mortality, after controlling for potential confounders (OR for severe case, 2.9, 95% CI 1.2-6.3, P = 0.007; OR for mortality, 2.9, 95% CI 1.2-6.7, P = 0.016). The associations were not statistically significant for further adjustment of inflammatory factors. CONCLUSION: TyG index was closely associated with the severity and morbidity in COVID-19 patients, thus it may be a valuable marker for identifying poor outcome of COVID-19.","Cardiovasc Diabetol","Ren, Huihui","Yang, Yan","Wang, Fen","Yan, Yongli","Shi, Xiaoli","Dong, Kun","Yu, Xuefeng","Zhang, Shujun","32393351"],"abstract":["BACKGROUND: The triglyceride and glucose index (TyG) has been proposed as a marker of insulin resistance. This study aims to evaluate the association of the TyG index with the severity and mortality of coronavirus disease 2019 (COVID-19). METHODS: The study included a cohort of 151 patients with COVID-19 admitted in a tertiary teaching hospital in Wuhan. Regression models were used to investigate the association between TyG with severity and mortality of COVID-19. RESULTS: In this cohort, 39 (25.8%) patients had diabetes, 62 (41.1%) patients were severe cases, while 33 (22.0%) patients died in hospital. The TyG index levels were significantly higher in the severe cases and death group (mild vs. severe 8.7 +/- 0.6 vs. 9.2 +/- 0.6, P < 0.001; survivor vs. deceased 8.8 +/- 0.6 vs. 9.3 +/- 0.7, P < 0.001), respectively. The TyG index was significantly associated with an increased risk of severe case and mortality, after controlling for potential confounders (OR for severe case, 2.9, 95% CI 1.2-6.3, P = 0.007; OR for mortality, 2.9, 95% CI 1.2-6.7, P = 0.016). The associations were not statistically significant for further adjustment of inflammatory factors. CONCLUSION: TyG index was closely associated with the severity and morbidity in COVID-19 patients, thus it may be a valuable marker for identifying poor outcome of COVID-19."],"journal":"Cardiovasc Diabetol","authors":["Ren, Huihui","Yang, Yan","Wang, Fen","Yan, Yongli","Shi, Xiaoli","Dong, Kun","Yu, Xuefeng","Zhang, Shujun"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32393351","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1186/s12933-020-01035-2","keywords":["covid-19","mortality","severity","tyg index"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666627827967983618,"score":9.490897,"similar":[{"pmid":32473903,"title":"Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19?","text":["Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19?","BACKGROUND AND AIM: Diabetes in often associated with an increased severity and mortality in patients with COVID-19. We aimed to find out whether the severity and mortality in patients with diabetes with COVID-19 has any correlation to the level of glycemic control. METHODS: A Boolean search was made in PubMed database using the specific keywords related to our objectives up till May 14, 2020 and full text of article retrieved with the supplements published in English language. RESULTS: Two studies available so far have studied the outcomes of severity and mortality in patients with diabetes stratified on glycemic control. Both the studies have unequivocally found that patients with poorly-controlled hyperglycemia (blood glucose >180 mg/dl) have significantly higher level of poor prognostic markers biochemically, compared to the well-controlled arms (blood glucose <180 mg/dl). Moreover, significant increase in severity and mortality was observed in cohorts with poorly-controlled blood glucose due to any cause (diabetes or stress hyperglycemia), compared to the well-controlled cohorts with COVID-19, even after the adjustment of multiple confounders. CONCLUSIONS: Poorly-controlled hyperglycemia increases the severity and mortality in patients with COVID-19. All treating physician must strive for a good glycemic control (blood glucose <180 mg/dl) in patients with or without diabetes.","Diabetes Metab Syndr","Singh, Awadhesh Kumar","Singh, Ritu","32473903"],"abstract":["BACKGROUND AND AIM: Diabetes in often associated with an increased severity and mortality in patients with COVID-19. We aimed to find out whether the severity and mortality in patients with diabetes with COVID-19 has any correlation to the level of glycemic control. METHODS: A Boolean search was made in PubMed database using the specific keywords related to our objectives up till May 14, 2020 and full text of article retrieved with the supplements published in English language. RESULTS: Two studies available so far have studied the outcomes of severity and mortality in patients with diabetes stratified on glycemic control. Both the studies have unequivocally found that patients with poorly-controlled hyperglycemia (blood glucose >180 mg/dl) have significantly higher level of poor prognostic markers biochemically, compared to the well-controlled arms (blood glucose <180 mg/dl). Moreover, significant increase in severity and mortality was observed in cohorts with poorly-controlled blood glucose due to any cause (diabetes or stress hyperglycemia), compared to the well-controlled cohorts with COVID-19, even after the adjustment of multiple confounders. CONCLUSIONS: Poorly-controlled hyperglycemia increases the severity and mortality in patients with COVID-19. All treating physician must strive for a good glycemic control (blood glucose <180 mg/dl) in patients with or without diabetes."],"journal":"Diabetes Metab Syndr","authors":["Singh, Awadhesh Kumar","Singh, Ritu"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32473903","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.dsx.2020.05.037","keywords":["covid-19","diabetes","glycemic control","mortality","sars-cov-2","severity"],"locations":["Boolean"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668341932744507393,"score":258.62372},{"pmid":32391877,"title":"Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019.","text":["Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019.","AIMS: To investigate the characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 (COVID-19). METHODS AND RESULTS: We enrolled 671 eligible hospitalized patients with severe COVID-19 from 1 January to 23 February 2020, with a median age of 63 years. Clinical, laboratory, and treatment data were collected and compared between patients who died and survivors. Risk factors of death and myocardial injury were analysed using multivariable regression models. A total of 62 patients (9.2%) died, who more often had myocardial injury (75.8% vs. 9.7%; P < 0.001) than survivors. The area under the receiver operating characteristic curve of initial cardiac troponin I (cTnI) for predicting in-hospital mortality was 0.92 [95% confidence interval (CI), 0.87-0.96; sensitivity, 0.86; specificity, 0.86; P < 0.001]. The single cut-off point and high level of cTnI predicted risk of in-hospital death, hazard ratio (HR) was 4.56 (95% CI, 1.28-16.28; P = 0.019) and 1.25 (95% CI, 1.07-1.46; P = 0.004), respectively. In multivariable logistic regression, senior age, comorbidities (e.g. hypertension, coronary heart disease, chronic renal failure, and chronic obstructive pulmonary disease), and high level of C-reactive protein were predictors of myocardial injury. CONCLUSION: The risk of in-hospital death among patients with severe COVID-19 can be predicted by markers of myocardial injury, and was significantly associated with senior age, inflammatory response, and cardiovascular comorbidities.","Eur Heart J","Shi, Shaobo","Qin, Mu","Cai, Yuli","Liu, Tao","Shen, Bo","Yang, Fan","Cao, Sheng","Liu, Xu","Xiang, Yaozu","Zhao, Qinyan","Huang, He","Yang, Bo","Huang, Congxin","32391877"],"abstract":["AIMS: To investigate the characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 (COVID-19). METHODS AND RESULTS: We enrolled 671 eligible hospitalized patients with severe COVID-19 from 1 January to 23 February 2020, with a median age of 63 years. Clinical, laboratory, and treatment data were collected and compared between patients who died and survivors. Risk factors of death and myocardial injury were analysed using multivariable regression models. A total of 62 patients (9.2%) died, who more often had myocardial injury (75.8% vs. 9.7%; P < 0.001) than survivors. The area under the receiver operating characteristic curve of initial cardiac troponin I (cTnI) for predicting in-hospital mortality was 0.92 [95% confidence interval (CI), 0.87-0.96; sensitivity, 0.86; specificity, 0.86; P < 0.001]. The single cut-off point and high level of cTnI predicted risk of in-hospital death, hazard ratio (HR) was 4.56 (95% CI, 1.28-16.28; P = 0.019) and 1.25 (95% CI, 1.07-1.46; P = 0.004), respectively. In multivariable logistic regression, senior age, comorbidities (e.g. hypertension, coronary heart disease, chronic renal failure, and chronic obstructive pulmonary disease), and high level of C-reactive protein were predictors of myocardial injury. CONCLUSION: The risk of in-hospital death among patients with severe COVID-19 can be predicted by markers of myocardial injury, and was significantly associated with senior age, inflammatory response, and cardiovascular comorbidities."],"journal":"Eur Heart J","authors":["Shi, Shaobo","Qin, Mu","Cai, Yuli","Liu, Tao","Shen, Bo","Yang, Fan","Cao, Sheng","Liu, Xu","Xiang, Yaozu","Zhao, Qinyan","Huang, He","Yang, Bo","Huang, Congxin"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391877","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1093/eurheartj/ehaa408","keywords":["coronavirus disease 2019","mortality","myocardial injury","risk"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666528580191911936,"score":255.00623},{"pmid":32345072,"pmcid":"PMC7196920","title":"The role of essential organ-based comorbidities in the prognosis of COVID-19 infection patients.","text":["The role of essential organ-based comorbidities in the prognosis of COVID-19 infection patients.","Objectives: To assess the role of essential organ-based comorbidities in the prognosis of COVID-19 patients.Methods: All consecutive patients diagnosed with COVID-19 admitted to the Zhongnan Hospital of Wuhan University from 11 January to 16 March 2020 were enrolled in this retrospective cohort study.Results: A total of 212 COVID-19 patients were included. COVID-19 patients with heart, liver and kidneycomorbidity, compared to patients without related comorbidities, were more likely to have cardiac injuries [9.1%(3/33) vs 2.2%(4/179), P = 0.043], liver injuries [13.0%(3/23) vs 3.2%(6/189), P = 0.027], kidney injury [54.5%(6/11) vs 2.0%(4/201), P < 0.001], and higher risk of mortality [Heart-comorbidity: 6.1%(2/33) vs 0.6%(1/179), P = 0.014; Liver-comorbidity: 8.7%(2/23) vs 0.5%(1/189), P = 0.002; Kidney-comorbidity: 27.3%(3/11) vs 1.0%(2/201), P < 0.001. Mortality was higher in patients with more severe Grade of organ injuries [Heart-injury: P = 0.044; Liver-injury: P = 0.020; Kidney-injury: P = 0.030].Conclusion: Male, older, co-existing of heart, liver, and kidney comorbidities, especially those with severe Grade organ injuries, had a poor prognosis after SARS-CoV-2 infection.","Expert Rev Respir Med","Yang, Rongrong","Gui, Xien","Zhang, Yongxi","Xiong, Yong","32345072"],"abstract":["Objectives: To assess the role of essential organ-based comorbidities in the prognosis of COVID-19 patients.Methods: All consecutive patients diagnosed with COVID-19 admitted to the Zhongnan Hospital of Wuhan University from 11 January to 16 March 2020 were enrolled in this retrospective cohort study.Results: A total of 212 COVID-19 patients were included. COVID-19 patients with heart, liver and kidneycomorbidity, compared to patients without related comorbidities, were more likely to have cardiac injuries [9.1%(3/33) vs 2.2%(4/179), P = 0.043], liver injuries [13.0%(3/23) vs 3.2%(6/189), P = 0.027], kidney injury [54.5%(6/11) vs 2.0%(4/201), P < 0.001], and higher risk of mortality [Heart-comorbidity: 6.1%(2/33) vs 0.6%(1/179), P = 0.014; Liver-comorbidity: 8.7%(2/23) vs 0.5%(1/189), P = 0.002; Kidney-comorbidity: 27.3%(3/11) vs 1.0%(2/201), P < 0.001. Mortality was higher in patients with more severe Grade of organ injuries [Heart-injury: P = 0.044; Liver-injury: P = 0.020; Kidney-injury: P = 0.030].Conclusion: Male, older, co-existing of heart, liver, and kidney comorbidities, especially those with severe Grade organ injuries, had a poor prognosis after SARS-CoV-2 infection."],"journal":"Expert Rev Respir Med","authors":["Yang, Rongrong","Gui, Xien","Zhang, Yongxi","Xiong, Yong"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32345072","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1080/17476348.2020.1761791","keywords":["covid-19","emerging infectious disease","cardiac injury","comorbidities","coronavirus disease 2019","kidney injury","liver injury"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495414960128,"score":249.87163},{"pmid":32437016,"title":"Obesity predisposes to the risk of higher mortality in young COVID-19 patients.","text":["Obesity predisposes to the risk of higher mortality in young COVID-19 patients.","BACKGROUND: Although emerging data demonstrated mortality of young COVID-19 patients, but no data reported the risk factors of mortality for those young patients, and whether obesity is a risk for young COVID-19 patients remains unknown. METHODS: We conducted a retrospective study including 13 young patients died of COVID-19 and 40 matched survivors. Logistic regression was employed to characterize the risk factors of mortality in young obese COVID-19 patients. RESULTS: Most of the young deceased COVID-19 patients were mild cases at the time of admission, but the disease progressed rapidly featured by the higher severity of Patchy shadows (100.00% vs. 48.70%, P = 0.006), pleural thickening (61.50% vs. 12.80%, P = 0.012), mild pericardial effusion (76.90% vs. 0.00%, P < 0.001). Most importantly, the deceased patients manifested higher BMI (OR = 1.354, 95% CI = 1.075-1.704, P = 0.010), inflammatory-related index CRP (OR = 1.014, 95% CI = 1.003-1.025, P = 0.014), cardiac injury biomarker hs-cTnI (OR = 1.420, 95% CI = 1.112-1.814, P = 0.005), and increased coagulation activity biomarker D-Dimer (OR = 418.7, P = 0.047), as compared to that of survivors. CONCLUSIONS: Our data support that obesity could be a risk factor associated with high mortality in young COVID-19 patients, while aggravated inflammatory response, enhanced cardiac injury and increased coagulation activity are likely to be the mechanisms contributing to the high mortality. This article is protected by copyright. All rights reserved.","J Med Virol","Zhang, Fengqin","Xiong, Ying","Wei, Yanqiu","Hu, Yi","Wang, Feng","Li, Gang","Liu, Kui","Du, Ronghui","Wang, Cong-Yi","Zhu, Wenzhen","32437016"],"abstract":["BACKGROUND: Although emerging data demonstrated mortality of young COVID-19 patients, but no data reported the risk factors of mortality for those young patients, and whether obesity is a risk for young COVID-19 patients remains unknown. METHODS: We conducted a retrospective study including 13 young patients died of COVID-19 and 40 matched survivors. Logistic regression was employed to characterize the risk factors of mortality in young obese COVID-19 patients. RESULTS: Most of the young deceased COVID-19 patients were mild cases at the time of admission, but the disease progressed rapidly featured by the higher severity of Patchy shadows (100.00% vs. 48.70%, P = 0.006), pleural thickening (61.50% vs. 12.80%, P = 0.012), mild pericardial effusion (76.90% vs. 0.00%, P < 0.001). Most importantly, the deceased patients manifested higher BMI (OR = 1.354, 95% CI = 1.075-1.704, P = 0.010), inflammatory-related index CRP (OR = 1.014, 95% CI = 1.003-1.025, P = 0.014), cardiac injury biomarker hs-cTnI (OR = 1.420, 95% CI = 1.112-1.814, P = 0.005), and increased coagulation activity biomarker D-Dimer (OR = 418.7, P = 0.047), as compared to that of survivors. CONCLUSIONS: Our data support that obesity could be a risk factor associated with high mortality in young COVID-19 patients, while aggravated inflammatory response, enhanced cardiac injury and increased coagulation activity are likely to be the mechanisms contributing to the high mortality. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zhang, Fengqin","Xiong, Ying","Wei, Yanqiu","Hu, Yi","Wang, Feng","Li, Gang","Liu, Kui","Du, Ronghui","Wang, Cong-Yi","Zhu, Wenzhen"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437016","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26039","keywords":["covid-19","cardiac damage","coagulation activity","inflammatory responses","obesity"],"locations":["obese","Patchy"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667521393762238464,"score":247.78111},{"pmid":32444493,"title":"Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy.","text":["Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy.","OBJECTIVE: To report clinical and laboratory characteristics, as well as treatment and clinical outcomes of patients admitted for neurologic diseases with and without COVID-19. METHODS: In this retrospective, single center cohort study, we included all adult inpatients with confirmed COVID-19, admitted to a Neuro-COVID Unit from February 21, 2020, who had been discharged or died by April 5, 2020. Demographic, clinical, treatment, and laboratory data were extracted from medical records and compared (FDR-corrected) to those of neurologic patients without COVID-19 admitted in the same period. RESULTS: One hundred seventy-three patients were included in this study, of whom 56 were positive for COVID-19 while 117 were negative for COVID-19. Patients with COVID-19 were older (77.0, IQR 67.0-83.8 vs 70.1, IQR 52.9-78.6, p = 0.006), had a different distribution regarding admission diagnoses, including cerebrovascular disorders (n = 43, 76.8% vs n = 68, 58.1%), and had a higher quick Sequential Organ Failure Assessment (qSOFA) score on admission (0.5, IQR 0.4-0.6 vs 0.9, IQR 0.7-1.1, p = 0.006). In-hospital mortality rates (n = 21, 37.5% vs n = 5, 4.3%, p < 0.001) and incident delirium (n = 15, 26.8% vs n = 9, 7.7%, p = 0.003) were significantly higher in the COVID-19 group. COVID-19 and non-COVID patients with stroke had similar baseline characteristics but patients with COVID-19 had higher modified Rankin scale scores at discharge (5.0, IQR 2.0-6.0 vs 2.0, IQR 1.0-3.0, p < 0.001), with a significantly lower number of patients with a good outcome (n = 11, 25.6% vs n = 48, 70.6%, p < 0.001). In patients with COVID-19, multivariable regressions showed increasing odds of in-hospital death associated with higher qSOFA scores (OR 4.47, 95% CI 1.21-16.5; p = 0.025), lower platelet count (0.98, 0.97-0.99; p = 0.005) and higher lactate dehydrogenase (1.01, 1.00-1.03; p = 0.009) on admission. CONCLUSIONS: COVID-19 patients admitted with neurologic disease, including stroke, have a significantly higher in-hospital mortality, incident delirium and higher disability than patients without COVID-19.","Neurology","Benussi, Alberto","Pilotto, Andrea","Premi, Enrico","Libri, Ilenia","Giunta, Marcello","Agosti, Chiara","Alberici, Antonella","Baldelli, Enrico","Benini, Matteo","Bonacina, Sonia","Brambilla, Laura","Caratozzolo, Salvatore","Cortinovis, Matteo","Costa, Angelo","Piccinelli, Stefano Cotti","Cottini, Elisabetta","Cristillo, Viviana","Delrio, Ilenia","Filosto, Massimiliano","Gamba, Massimo","Gazzina, Stefano","Gilberti, Nicola","Gipponi, Stefano","Imarisio, Alberto","Invernizzi, Paolo","Leggio, Ugo","Leonardi, Matilde","Liberini, Paolo","Locatelli, Martina","Masciocchi, Stefano","Poli, Loris","Rao, Renata","Risi, Barbara","Rozzini, Luca","Scalvini, Andrea","Schiano di Cola, Francesca","Spezi, Raffaella","Vergani, Veronica","Volonghi, Irene","Zoppi, Nicola","Borroni, Barbara","Magoni, Mauro","Pezzini, Alessandro","Padovani, Alessandro","32444493"],"abstract":["OBJECTIVE: To report clinical and laboratory characteristics, as well as treatment and clinical outcomes of patients admitted for neurologic diseases with and without COVID-19. METHODS: In this retrospective, single center cohort study, we included all adult inpatients with confirmed COVID-19, admitted to a Neuro-COVID Unit from February 21, 2020, who had been discharged or died by April 5, 2020. Demographic, clinical, treatment, and laboratory data were extracted from medical records and compared (FDR-corrected) to those of neurologic patients without COVID-19 admitted in the same period. RESULTS: One hundred seventy-three patients were included in this study, of whom 56 were positive for COVID-19 while 117 were negative for COVID-19. Patients with COVID-19 were older (77.0, IQR 67.0-83.8 vs 70.1, IQR 52.9-78.6, p = 0.006), had a different distribution regarding admission diagnoses, including cerebrovascular disorders (n = 43, 76.8% vs n = 68, 58.1%), and had a higher quick Sequential Organ Failure Assessment (qSOFA) score on admission (0.5, IQR 0.4-0.6 vs 0.9, IQR 0.7-1.1, p = 0.006). In-hospital mortality rates (n = 21, 37.5% vs n = 5, 4.3%, p < 0.001) and incident delirium (n = 15, 26.8% vs n = 9, 7.7%, p = 0.003) were significantly higher in the COVID-19 group. COVID-19 and non-COVID patients with stroke had similar baseline characteristics but patients with COVID-19 had higher modified Rankin scale scores at discharge (5.0, IQR 2.0-6.0 vs 2.0, IQR 1.0-3.0, p < 0.001), with a significantly lower number of patients with a good outcome (n = 11, 25.6% vs n = 48, 70.6%, p < 0.001). In patients with COVID-19, multivariable regressions showed increasing odds of in-hospital death associated with higher qSOFA scores (OR 4.47, 95% CI 1.21-16.5; p = 0.025), lower platelet count (0.98, 0.97-0.99; p = 0.005) and higher lactate dehydrogenase (1.01, 1.00-1.03; p = 0.009) on admission. CONCLUSIONS: COVID-19 patients admitted with neurologic disease, including stroke, have a significantly higher in-hospital mortality, incident delirium and higher disability than patients without COVID-19."],"journal":"Neurology","authors":["Benussi, Alberto","Pilotto, Andrea","Premi, Enrico","Libri, Ilenia","Giunta, Marcello","Agosti, Chiara","Alberici, Antonella","Baldelli, Enrico","Benini, Matteo","Bonacina, Sonia","Brambilla, Laura","Caratozzolo, Salvatore","Cortinovis, Matteo","Costa, Angelo","Piccinelli, Stefano Cotti","Cottini, Elisabetta","Cristillo, Viviana","Delrio, Ilenia","Filosto, Massimiliano","Gamba, Massimo","Gazzina, Stefano","Gilberti, Nicola","Gipponi, Stefano","Imarisio, Alberto","Invernizzi, Paolo","Leggio, Ugo","Leonardi, Matilde","Liberini, Paolo","Locatelli, Martina","Masciocchi, Stefano","Poli, Loris","Rao, Renata","Risi, Barbara","Rozzini, Luca","Scalvini, Andrea","Schiano di Cola, Francesca","Spezi, Raffaella","Vergani, Veronica","Volonghi, Irene","Zoppi, Nicola","Borroni, Barbara","Magoni, Mauro","Pezzini, Alessandro","Padovani, Alessandro"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32444493","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1212/WNL.0000000000009848","locations":["Rankin","Brescia","Lombardy","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667600475896152064,"score":243.32721}]}